Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR1 rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02706691 | Phase II | Infigratinib | Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer | Terminated | USA | 0 |
NCT04601857 | Phase II | Futibatinib + Pembrolizumab | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | Active, not recruiting | USA | FRA | ESP | 0 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Active, not recruiting | USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT04294277 | Phase II | Pemigatinib | Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS) | Terminated | ITA | 0 |
NCT03834220 | Phase II | Zoligratinib | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Terminated | USA | ROU | POL | NOR | NLD | HRV | GRC | GBR | FRA | FIN | ESP | DNK | CZE | BRA | BGR | AUT | AUS | 6 |
NCT04233567 | Phase II | Infigratinib | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Active, not recruiting | USA | 0 |
NCT05216120 | Phase II | Pemigatinib | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Withdrawn | USA | 0 |
NCT03801434 | Phase II | Ruxolitinib | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Recruiting | USA | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 1 |
NCT02268253 | Phase II | Tagraxofusp-erzs | Tagraxofusp (SL-401) in Patients With CMML or MF | Completed | USA | CAN | 0 |
NCT06302621 | Phase I | Afatinib + Pemigatinib | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT01975701 | Phase II | Infigratinib | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | Completed | USA | NLD | ESP | CHE | BEL | AUS | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06653777 | Phase II | Pemigatinib | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells (AcSe PEMI) | Not yet recruiting | FRA | 0 |
NCT03011372 | Phase II | Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | 1 |
NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
NCT04096417 | Phase II | Pemigatinib | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | Active, not recruiting | USA | 0 |
NCT04003623 | Phase II | Pemigatinib | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | Terminated | USA | 0 |
NCT03611868 | Phase Ib/II | Alrizomadlin + Pembrolizumab Alrizomadlin | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | AUS | 0 |